Pancreatic Cancer Pipeline constitutes 290+ key companies continuously working towards developing 300+ Pancreatic Cancer treatment therapies, analyzes DelveInsight.
Pancreatic Cancer Overview:
Pancreatic cancer develops when malignant cells form in the pancreas, a gland situated behind the stomach. It often begins from precancerous changes such as pancreatic intraepithelial neoplasia (PanIN), but may also arise from larger precursor lesions like intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms. The disease is marked by disrupted cellular signaling that enhances cancer cell growth, movement, invasion, and spread.
Additionally, pancreatic cancer is associated with altered metabolism and resistance to signals that normally suppress cell growth. A key example is the dysregulation of the TGFβ signaling pathway. While TGFβ typically acts as a tumor suppressor, in pancreatic cancer, its overexpression contributes to disease progression by promoting tumor growth and metastasis. It can also activate alternative signaling pathways—such as MAPK, Src, AKT, and WNT7B—further driving cancer cell proliferation and survival.
Request for a detailed insights report on Pancreatic Cancer pipeline insights @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
“Pancreatic Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Cancer Therapeutics Market.
Key Takeaways from the Pancreatic Cancer Pipeline Report
DelveInsight’s Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
In December 2025, Zai Lab Limited and Novocure announced that the Phase 3 PANOVA-3 trial successfully met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) compared to the control group. The trial evaluated the combination of Tumor Treating Fields (TTFields) therapy with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Key Pancreatic Cancer companies such as ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others are evaluating new drugs for Pancreatic Cancer to improve the treatment landscape.
Promising Pancreatic Cancer pipeline therapies in various stages of development include Pamrevlumab, Devimistat, Masitinib, SBP-101, TAS-102, RAIN-32, IMX-110, and others.
Pancreatic Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Pancreatic Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pancreatic Cancer market.
Download our free sample page report on Pancreatic Cancer pipeline insights @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Pancreatic Cancer Emerging Drugs
Pamrevlumab: FibroGen
Devimistat: Cornerstone Pharmaceuticals
Masitinib: AB Science
SBP-101: Panbela Therapeutics
TAS-102: Taiho Pharmaceutical Co., Ltd.
RAIN-32: Rain Oncology
IMX-110: Immix Biopharma
Pancreatic Cancer Companies
Over 290 leading companies are actively working on developing therapies for pancreatic cancer. Among them, FibroGen has drug candidates in the late-stage Phase III of clinical development.
DelveInsight’s report covers around 300+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Pancreatic Cancer Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Cancer Therapies and Key Companies: Pancreatic Cancer Clinical Trials and advancements
Pancreatic Cancer Pipeline Therapeutic Assessment
• Pancreatic Cancer Assessment by Product Type
• Pancreatic Cancer By Stage
• Pancreatic Cancer Assessment by Route of Administration
• Pancreatic Cancer Assessment by Molecule Type
Download Pancreatic Cancer Sample report to know in detail about the Pancreatic Cancer treatment market @ Pancreatic Cancer Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Pancreatic Cancer Current Treatment Patterns
4. Pancreatic Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Cancer Late-Stage Products (Phase-III)
7. Pancreatic Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Cancer Discontinued Products
13. Pancreatic Cancer Product Profiles
14. Pancreatic Cancer Key Companies
15. Pancreatic Cancer Key Products
16. Dormant and Discontinued Products
17. Pancreatic Cancer Unmet Needs
18. Pancreatic Cancer Future Perspectives
19. Pancreatic Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Pancreatic Cancer Pipeline Reports Offerings
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
